Objective: We investigated the prevalence of Lynch syndrome and Lynch-like syndrome among Japanese colorectal cancer patients, as there have been no credible data from Japan. Methods: Immunohistochemical analyses for mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) were carried out in surgically resected, formalin-fixed paraffin-embedded specimens obtained from 1,234 newly diagnosed colorectal cancer patients between March 2005 and April 2014. The presence/absence of the BRAF V600E mutation and hypermethylation of the MLH1 promoter was analyzed where necessary. Genetic testing was finally undertaken in patients suspected as having Lynch syndrome. Results: By the universal screening approach with immunohistochemical analysis for mismatch repair proteins followed by analyses for the BRAF V600E mutation and MLH1 promoter methylation status, 11 (0.9%) of the 1,234 patients were identified as candidates for genetic testing. Out of the 11 patients, 9 (0.7%) were finally diagnosed as having Lynch syndrome; the responsible genes included MLH1 (n = 1), MSH2 (n = 4), EPCAM (n = 1) and MSH6 (n = 3). The remaining two patients (0.2%) were regarded as having Lynch-like syndrome, since biallelic somatic deletion of the relevant mismatch repair genes was detected in the absence of germline mismatch repair alterations. None of the cases was identified as having germline MLH1 epimutation. Conclusions: The prevalence of Lynch syndrome among all newly diagnosed cases of colorectal cancer in Japan is in the same range as that recently reported by studies in Western population. The prevalence of Lynch-like syndrome seems to be extremely low.
Introduction
Lynch syndrome (LS), an autosomal-dominant inherited disorder that is characterized by germline mutations in one or more of the mismatch repair (MMR) genes (mutL homolog 1 [MLH1], mutS homolog 2 [MSH2], mutS homolog 6 [MSH6] , and postmeiotic segregation increased 2 [PMS2]), is the most common form of hereditary colorectal cancer (CRC) (1) . This syndrome is also characterized by an increased risk, in particular, of early onset CRC and endometrial cancer, as well as an increased risk of other cancers including cancer of the stomach, ovary, ureter and renal pelvis, small bowel, bile duct, brain and skin (2) . Recent studies have shown that LS can sometimes be also caused by epigenetic alterations in the germline (3) . Inactivation of MSH2 by hypermethylation of the MSH2 promoter caused by deletion of 3′ portion of EPCAM (epithelial cell adhesion molecule) constitutes a unique subgroup of LS (4) . In addition, constitutional epimutation (MLH1 promoter methylation in the germline) has also been reported as a rare cause of LS (5) .
In LS-associated tumors, somatic inactivation or the so-called "second-hit" of the wild-type allele of the affected MMR gene leads to abnormal functioning of the gene with accumulation of errors during DNA replication, especially in repetitive sequences known as microsatellites. Consequently, such tumors characteristically exhibit MMR deficiency, as reflected by high-level (high-frequency) microsatellite instability (MSI-H) and/or loss of MMR protein expression, which are the hallmarks of this disorder (6) .
It has been reported that LS occurs at a prevalence rate of 1-5% among unselected patients with CRC (7) . Recent studies (8) (9) (10) (11) (12) (13) carried out in Western countries using the universal screening approach, in which all newly diagnosed cases of CRC are subjected to MSI testing and/or immunohistochemistry (IHC) for MMR proteins, reported a prevalence of LS in the range of 0.7% (10) to 3.7% (11) . The prevalence of LS may differ among ethnicities, races and countries because of a lack of sufficient data and may be influenced by selection biases in studies or by the age distribution of the study cohort. In addition, a lifetime risk of developing CRC among carriers of the mutations may be influenced by environmental factors and the lifestyles (14) (15) (16) (17) . Under these circumstances, there have been no credible data on the prevalence of LS among CRC patients in Japan, which represents one of the most rapidly aging societies in the world, and where CRC was estimated in 2015 as being the most frequently occurring of all malignant tumors and also as being the first and second leading causes of death in women and men, respectively (18) .
Recently, a subset of patients with MMR-deficient tumors has been identified as having Lynch-like syndrome (LLS) (19) ; patients with LLS exhibit MMR deficiency in the tumor, but the carcinogenesis is not associated with the serrated pathway and germline testing fails to reveal any pathogenic mutations (19) . The prevalence and clinicopathologic characteristics of LLS among CRC patients in the Japanese population are still poorly understood.
We previously reported, based on our analysis of 138 CRC patients younger than 60 years by both IHC for MMR proteins and MSI testing, that the prevalence of LS among Japanese CRC patients might be lower than those reported from Western countries (20) . This study was undertaken as an extension of this previous study to determine the prevalence of LS and LLS in a Japanese hospital-based population, which seems to show a high level of ethnic homogeneity, by using the universal screening approach, wherein specimens from all newly diagnosed CRC patients were examined by IHC for MMR proteins, followed by somatic BRAF mutation testing and somatic MLH1 promoter methylation analysis.
Materials and methods

Ethical considerations
This study was conducted with the approval of the Local Ethics Committee of Saitama Medical Center (No. 924, 925, 926 and 1355) and Saitama Medical University (No. 592 and 747). For the genetic testing of the MMR genes, informed consent was obtained from each patient. For the deceased cases, consent was obtained from the next-of-kin (family members).
Patient selection
A total of 1,234 consecutive newly diagnosed CRC patients who underwent surgery for removal of the primary tumor between March 2005 and April 2014 were enrolled in this study. The demographic and clinicopathologic data, and personal/family histories of the patients were obtained from the medical charts. Patients with metachronous CRC, familial adenomatous polyposis, ulcerative colitis or Crohn's disease were excluded. In patients with synchronous CRCs, the tumor that showed the greater depth of invasion on histologic examination than the other(s) or whose diameter was larger than that of the other(s) was considered as the representative tumor. Our previous study (20) was conducted in 138 CRC patients younger than 60 years old who had undergone surgery between January 2005 and August 2010, and data from these patients were included in the analyses in this study.
IHC for MMR proteins
IHC was performed for four MMR proteins (MLH1, MSH2, MSH6 and PMS2) using a Staining Automat (BOND III; Leica Biosystems Melbourne Pvt. Ltd, Melbourne, Australia), according to the manufacturer's protocol, in 4-μm-thick formalin-fixed paraffinembedded (FFPE) sections. The primary antibodies used for detecting the MMR proteins were anti-hMLH1 antibody (clone ES05; Leica Biosystems Newcastle Ltd, Newcastle, UK; 1:100), antihMSH2 antibody (clone 25D12; Leica Biosystems Newcastle Ltd; 1:100), anti-hMSH6 antibody (clone PU29; Leica Biosystems Newcastle Ltd; 1:70) and anti-hPMS2 antibody (clone M0R4G; Leica Biosystems Newcastle Ltd; 1: 40).
The normal staining patterns for MLH1, MSH2, MSH6 and PMS2 are nuclear. The absence of nuclear staining in the tumor cells in the presence of nuclear staining of non-neoplastic cells, such as normal colonic epithelial cells, lymphocytes or stromal cells was considered to represent an abnormal pattern (Supplementary Figure 1) . The staining results were assessed by consensus between two independent pathologists (J.T. and T.T.) and a colorectal surgeon (N.C.), all of whom were blinded to the clinical status of the patients.
DNA extraction
DNA was extracted from leukocytes, frozen tissue specimens prepared just after tumor resection and stored at −80°C and/or 10-μm-thick FFPE sections of the normal colonic mucosa or cancer tissue.
DNA from the leukocytes and frozen tissue specimens was extracted using the QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany), while that from the FFPE sections was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen).
Sanger sequencing
Sanger sequencing was performed using amplified DNA fragments, the indicated primers, the BigDye 3.1 cycle sequencing kit (Thermo Fisher Scientific Inc., Waltham, MA) and the ABI 3500 Genetic analyzer (Thermo Fisher Scientific Inc.).
BRAF V600E mutation analysis
In cases where the IHC analysis of the cancer tissues demonstrated loss of both MLH1 and PMS2, the mutation status of Exon 15 of the BRAF gene, BRAF V600E (c.1799T > A, p.Val600Glu) in the cancer tissues was assessed by Sanger sequencing, as described previously (21) .
Methylation analysis of the MLH1 gene promoter C region
In cases where the above analysis revealed no BRAF mutations, methylation analysis of the MLH1 promoter C region was performed in FFPE specimens of the tumors and normal mucosa. After laser microdissection of cancer cells using Leica LMD 7000 (Leica Microsystems GmbH, Wetzlar, Germany), DNA was isolated from the collected tissue samples using the QIAamp DNA FFPE Tissue Kit (Qiagen). Bisulfite conversion of the extracted DNA was conducted using the innuCONVERT Bisulfite Basic Kit (AJ Innuscreen GmbH, Berlin, Germany). The promoter C region of MLH1 was amplified using the following primers, as described previously (22): MLH1C_BS_F01: 5′-TTTTAAAAAYGAATTAATAGGA-3′ and MLH1C_BS_R01: 5′-AAATACCAATCAAATTTCTCAA-3′. Sanger sequencing was conducted using the MLH1C_BS_R01. When only a cytosine residue signal was observed at the CpG sites in the MLH1 promoter C region, the sample was classified as "hypermethylated," while when only a thymine residue signal was observed at the CpG sites, the sample was classified as "unmethylated." Furthermore, samples showing both cytosine and thymidine residues at the CpG sites were categorized as "heterozygously methylated."
Detection of germline mutations and copy number variances
The full sequence analysis of the MMR genes in the germline, extracted from the blood or FFPE specimens of normal mucosa, was performed using the direct sequencing method. Analysis of the MLH1 and MSH2 genes was performed according to the protocol provided by Thermo Fisher Scientific (Development of a resequencing Workflow for variant analysis of MLH1 and MSH2), while sequencing of the MSH6 gene was performed as described previously (23) .
When no deleterious (pathogenic) mutations were detected by Sanger sequencing, a multiplex ligation-dependent probe amplification (MLPA) method was used for analysis of the copy number variance of the exons of the MLH1, MSH2 and EPCAM genes using Salsa ® MLPA ® kit P-003 (MRC-Holland, Amsterdam, the Netherlands).
The identified variants were assessed by the InSiGHT classification criteria (24) . The variants categorized into Class 4 or Class 5 were considered to be pathogenic in this study.
Statistical analysis
Data are expressed as medians and range, as appropriate. Categorical data were dichotomized where appropriate, and comparisons between groups were carried out using the Fisher's exact probability test. Continuous variables between the groups were compared with the Mann-Whitney test. P-value < 0.05 were denoted to be significant.
Results
Clinicopathologic characteristics
The clinicopathologic features of the patients included in this study are summarized in Table 1 . There were 752 men and 482 women. The median age of the patients was 69 years (range: 24-97 years). When the subjects were stratified by age, there were 7 (0.6%) patients who were 29 years of age or younger, 19 (1.5%) patients in their 30s, 42 (3.4%) patients in their 40s, 173 (14.1%) patients in their 50s, 410 (33.2%) patients in their 60s, 422 (34.2%) patients in their 70s and 161 (13.0%) patients who were 80 years of age or older. The site of the primary tumor was distributed as follows; cecum, 91 cases (7.4%); ascending colon, 200 cases (16.2%); transverse colon, 130 cases (10.5%); descending colon, 60 cases (4.9%); sigmoid colon, 338 cases (27.4%); rectum, 415 cases (33.6%). The histological diagnoses/tumor differentiation grade according to the classification of the General Rules for Cancer of the Colon, Rectum, and Anus in Japan (25) were as follows: well-differentiated adenocarcinoma (n = 407), moderately differentiated adenocarcinoma (n = 746), poorly differentiated adenocarcinoma (n = 62), mucinous carcinoma (n = 17) and signet-ring cell carcinoma (n = 2). The tumors were staged according to the seventh edition of the TNM-UICC classification (26) (27) , while 201 patients met at least one of the 5 criteria of the revised Bethesda guidelines (28) .
IHC for MMR proteins followed by the analysis for the BRAF V600E mutation and methylation of the MLH1 promoter C region
The flow chart for screening and identification of LS and LLS is shown in Fig. 1 . In the IHC evaluation, loss of any MMR protein expression was observed in 61 patients (4.9%). Loss of expression of both MLH1 and PMS2 was observed in 52 patients, loss of expression of both MSH2 and MSH6 was observed in 6 patients and isolated loss of MSH6 expression was observed in 3 patients; there were no patients with isolated loss of PMS2 expression.
Among the 52 patients (4.2%) with loss of both MLH1 and PMS2, BRAF V600E mutation was detected in 28 (2.3%) patients. MLH1 promoter methylation analysis in the 24 (1.9%) tumors without the BRAF V600E mutation demonstrated "hypermethylation" in 22 tumors (1.8%), "heterozygous methylation" in 1 tumor (0.08%) and "no methylation" in 1 tumor (0.08%). Methylation analysis of FFPE specimens of normal mucosa from the 22 patients with tumors that showed "hypermethylation" failed to reveal methylation of the MLH1 promoter C region in any of the patients, strongly indicating that there were no patients with constitutional epimutation of the MLH1 gene.
Identification of LS and LLS
As shown in Fig.1 , a total of 11 (0.9%) patients were identified by the screening evaluations as candidates for germline MMR mutation analysis. Of the 11 patients, 6 with both MSH2 and MSH6 loss and 3 with isolated MSH6 loss underwent germline mutation testing for either MSH2 and/or EPCAM, or MSH6; the remaining two patients with loss of both MLH1 and PMS2, and with either "heterozygous methylation" (n = 1) or "no methylation" (n = 1) of the MLH1 promoter in the tumor underwent germline mutation testing for MLH1.
The germline mutation analysis revealed deleterious pathogenic mutations, based on the InSiGHT database, in 9 of the 11 patients (0.7% of the entire analysis set).
In the two patients with MLH1/ PMS2 loss (n = 1) or MSH2/ MSH6 loss (n = 1) in whom the relevant germline MMR gene mutation could not be identified, possible somatic inactivation of the relevant MMR genes (MLH1 or MSH2) was examined. The tumors from both of these patients showed biallelic loss of the relevant MMR genes, leading to the diagnosis of LLS (Suppl. Figure 2A, 2B) .
The details of the types of mutations (alterations) and clinicopathologic factors, including fulfillment of the revised Bethesda guidelines, in the identified LS and LLS patients are shown in Table 2 .
Concerning the LS patients, there were seven men and two women with a median age of 55 years (range, 24-79 years). The responsible genes associated with LS were MLH1 (n = 1), MSH2 (n = 4), EPCAM (n = 1) and MSH6 (n = 3). The same pathogenic mutation in MSH6 (c.1806_1809delAAAG) was identified in two patients, but these patients belonged to unrelated families. The case with EPCAM deletion has already been reported (29) separately from this study.
The sites of the primary tumor in the patients with LS were as follows: right-sided colon, five patients; left-sided colon, one patient; rectum, three patients. Histologic examination revealed well-differentiated adenocarcinoma in three patients, moderately differentiated adenocarcinoma in three patients, poorly differentiated adenocarcinoma in two patients and signet-ring cell carcinoma in one patient. Distribution of the disease stage in these patients according to the TNM classification was as follows: Stage 0, one patient; Stage II, seven patients; Stage III, one patient. Seven (78%) of the nine patients fulfilled at least one of the criteria of the revised Bethesda guidelines.
Comparison between patients with LS/LLS and other CRC patients Table 1 also shows a comparison of the demographic and clinicopathological characteristics, including family history of tumors, between patients with CRC associated with LS/LLS (n = 11) and other CRC patients (n = 1223). There was no significant difference in the male:female ratio between the two groups (P = 0.54). Patients in the LS/LLS group tended to be younger than the patients in the other CRC group (P = 0.052). The proportion of patients with right-sided colon cancer tended to be higher in the LS/LLS group as compared with that in the other group (P = 0.053). The LS/LLS group, as compared with the other group, showed a significantly higher proportion of cases with a poorly differentiated type histology (poorly differentiated adenocarcinoma, mucinous carcinoma or signet-ring cell carcinoma) (P < 0.01) and of cases fulfilling the revised Bethesda guidelines (P < 0.01); this group also tended to show a higher proportion of cases with a less advanced pathologic stage (Stage 0/I/II) (P = 0.07).
Proportion of CRC patients with LS, LLS and sporadic MMR deficiency according to the age and site of the primary tumor
As demonstrated above, nine (0.7%) and two (0.2%) patients were identified as having LS and LLS, respectively. CRC with sporadic MMR deficiency (hereafter, sporadic MMR-deficient CRC), as determined by the presence of the BRAF V600E mutation and/or somatic hypermethylation of the MLH1 promoter, which is known to be associated with the serrated carcinogenesis pathway (30) , was confirmed in 50 (4.1%) patients with a median age of 75 years (range, 51-94 years) and male to female ratio of 23:27. The numbers and proportions of patients with LS, LLS and sporadic MMR-deficient CRC are shown in Figs 2 and 3 . The proportion of cases with LS was the highest (14%) in patients in their 20s, followed by 6% in patients in their 30s and 5% in patients in their 40s. Notably, the proportion of LS cases in patients in their 50s, 60s and 70s ranged between 0.7% and 0.5%. There were no cases of LS identified in patients who were 80 years or older. Conversely, there were no cases of sporadic MMR deficiency identified among CRC patients who were 50 years or younger. The proportion of patients with sporadic MMR-deficient CRC ranged from 2% to 9.3% in patients of advanced age (those in their 50s to those in their 80s or older). Furthermore, when analyzed according to the site distribution of the primary tumor (right-sided colon versus left-sided colon/ rectum) ( Fig. 4A and B) , the frequency of patients with MMRdeficient CRC was 12.6% (53/421) and 1.0% (8/813) in the groups with right-sided colon cancer and left-sided colon/rectal cancer, respectively (P < 0.01). In addition, the frequencies of LS among patients with MMR-deficient tumors in the right-sided colon cancer group and left-sided colon/rectal cancer group were 9.4% (5/53) and 50% (4/8), respectively (P < 0.01).
Discussion
Since LS has been extensively characterized in Western countries, estimation of the prevalence of LS as in this study may not be novel. However, the true incidence of LS among all newly diagnosed CRC patients in Japan has not yet been reported. To the best of our knowledge, this is one of the most comprehensive studies performed to date, and the first, to clarify the incidence of LS among CRC patients in a Japanese hospital-based population.
In this study, we clarified several important results: (i) The incidence of LS among unselected newly diagnosed CRC patients was 0.7%, which might be lower than that reported previously (1-5%) (7), but within the same range (0.7-3.7%) (8) (9) (10) (11) (12) (13) as that reported by recent studies, mainly from Western countries, based on a universal screening approach of all newly diagnosed patients of CRC.
(ii) A selective screening approach such as that based on the Bethesda guidelines would have missed 24% of LS patients. (iii) A "heterozygous methylation" status of the MLH1 promoter in the tumor could not exclude the possibility of LS. (iv) There was no possibility to suspect the presence of germline MLH1 epimutation among those with MLH1/PMS2 loss. (v) The incidence of LLS was extremely low, being 0.2% among all the CRC patients studied. (vi) The clinicopathologic factors related to LS/LLS were in concordance with those previously reported from Western countries (1,2). The incidence (0.7%) of LS in this study may be a subject of debate. The incidence was within the range (0.7-3.7%) reported by recent studies conducted utilizing the universal screening approach. The incidence of LS determined by the universal screening approach, that is, evaluation of all newly diagnosed CRC patients, seems to be influenced by the proportion of geriatric patients in the study cohort. Most studies have not demonstrated the precise age distributions in their study cohorts. Notably, in one Australian study (13) , the results of universal screening of 1,046 newly diagnosed CRC patients revealed an incidence of LS of 0.8% and percentage of patients aged 70 years or older of 45.1%, which seem compatible with the data from this study, in which the percentage of patients who were aged 70 years or older was 47.2%.
According to previous reports,~90% of all germline mutations in LS patients are found in MLH1 and MSH2 (31, 32) . This study demonstrated that the most commonly occurring deleterious germline mutation was that noted in MSH2 (56%, 5/9 cases), which was in agreement with other studies from the USA (8), Finland (33), Spain (11), Slovenia (34) and Saudi Arabia (35) . The reason for the lower incidence of the MLH1 germline mutation (only one case) is unclear, despite the search for the possibility of germline MLH1 epimutations. One possible explanation is that cases with missense mutations in MLH1, which might lead to normal expression of MLH1 as assessed by IHC (36) , are possibly being missed, although the incidence of such cases among pathogenic MLH1 mutations seems to be negligibly low. The other explanation is that it is simply the result of contingency. Our results were from a single-institutional study; therefore, nationwide studies investigating the incidence of each gene responsible for LS, as well as the incidence of LS among newly diagnosed CRC patients is mandatory.
The gold standard for the diagnosis of LS is the detection of deleterious (pathogenic) germline mutations in one or more of the four MMR genes or deletion of EPCAM. However, adoption of an effective screening program that can accurately identify the majority of LS cases is the subject of continuing debate, with some groups advocating selective screening, while recent studies and guidelines strongly emphasize the role of a universal screening program for all patients with CRC (37, 38) , regardless of the clinicopathologic features or family history. Specifically, the NCCN guideline (38) recommends LS screening using either IHC or MSI testing of all newly diagnosed patients with CRC or newly diagnosed CRC patients younger than 70 years of age plus those 70 years or old who meet the Bethesda guidelines. This universal testing method with some modifications would help in identifying patients who should undergo further genetic testing for LS, regardless of the family history. Modern Japanese families, just like those from Western countries, tend to be smaller, and the small sizes of these families could lead to incomplete penetrance of the MMR mutations, making it difficult to identify LS. Under this circumstance, obtaining data of the age of onset of LS-associated tumors in the patients' relatives is difficult in clinical practice. Actually, in our previous research (39), the percentages of CRC patients who met the revised Amsterdam criteria (Amsterdam criteria II) and revised Bethesda guidelines based on the descriptions in the medical charts were 0 (0%) and 16.1%, respectively, among all the CRC patients who underwent surgery between April 2005 and January 2012; obtaining more precise information about the relatives' age at cancer diagnosis may have increased the values to 0.3% and 26.1%, respectively. Although a discussion on the optimal screening method for LS in Japan is out of the scope of this study, the universal screening approach may be potentially ideal even in Japan, since studies from Western countries have demonstrated that appropriate LS surveillance programs could be beneficial for the detection of LS and mutant carriers in relatives of LS patients, which would potentially lead to a reduction of the CRC incidence and mortality by 56-70% (40, 41) . However, considering the shift of CRC morbidity to geriatric populations, as well as the lack of reimbursement (no support from the governmental health insurance system) for IHC evaluation of MMR expression in Japan, an unquestioning acceptance of universal screening for all newly diagnosed CRC patients is an issue that would need contemplation. This study, for example, showed that the possibility of LS dramatically decreased in patients aged 70 years or older. In populations of this age,~290 CRC patients would need to be screened to identify one additional LS patient, which might represent an unfavorable cost-efficacy ratio, although the cost-efficacy ratio was not calculated. In addition, we should note that the incidence of MMR deficiency (4.9%) was compatible with that in previous reports (6-7%) (42) from Japan but much lower than the incidence of 12-16% (43-45) reported from Western countries. The incidences of patients with sporadic MMR deficiency, LS and LLS classified according to the age and primary tumor site clarified in this study would help in evaluating the efficacy of a universal screening approach in Japan.
With regard to the results of the MLH1 methylation analysis as a negative predictor of germline MMR mutations, the results have been known to vary depending on the promoter region analyzed (46) . Methylation of the MLH1 promoter A region was relatively common (up to 60%) in LS samples (47) . However, it has been reported that methylation of the MLH1 promoter C region was strongly associated with loss of tumor MLH1 expression through gene silencing (46, 48) . In a recent paper, methylation of the MLH1 promoter C region was observed in 15.8% (3/19) of tumors from carriers of pathogenic germline mutations of MLH1 (49). Actually, we detected one MLH1 germline mutation carrier in a microdissected specimen classified as showing "heterozygous methylation" of the MLH1 promoter C region. These observations prompted us to contemplate the potential risk of missing MLH1-deficient LS cases by simple MLH1 promoter methylation analyses, without considering the possibility of the second hit inactivation via promoter methylation in the cancer tissues of LS patients.
LLS is a new and evolving condition and may account for as much as 70% of all cases with suspected LS (19) . The term, "Lynch syndrome mimic" (50) or "Lynch syndrome-like" (51) seems to be a synonym of "Lynch-like syndrome." It is also possible that LLS patients may represent a heterogeneous group between sporadic MMR-deficient CRC patients and true LS patients. From a clinical viewpoint, LLS patients have a mean age of onset similar to LS patients and the only differentiating features between these two syndromes are the lower standardized incidence ratios for CRCs and non-CRC LS-associated tumors in LLS patients as compared with those in LS patients, though only limited data are available at present. Some investigators have reported that 50-60% of LLS-associated CRCs exhibit biallelic somatic inactivation of the MMR genes within the tumor (19, (52) (53) (54) (55) , through somatic mutations (nonsense, missense, frameshift or splicing site deletions, or loss of heterozygocity). In this study, we succeeded in identifying two cases of LLS: one showed biallelic somatic deletion of the entire MLH1 gene, while the other showed biallelic deletion of at least Exon 9 of EPCAM and the entire MSH2 gene. It is noteworthy that both of these deletion patterns have not been reported so far in cancer tissues from LLS patients. Elucidation of the mechanisms involved in biallelic inactivation of the MMR genes in patients with LLS warrants further investigation.
In conclusion, this study was the first to comprehensively investigate the prevalence of LS and LLS among newly diagnosed CRC patients based on a universal screening approach utilizing IHC evaluation for MMR expression. The true prevalences of LS and LLS, as well as the percentage of LS-associated genes, must be investigated in a nationwide study.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online.
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